Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report
Introduction: Chemoimmunotherapy is associated with promising activity in mesothelioma in phase II to III trials. Studies exploring this approach in patients ineligible for clinical trials are lacking. We assembled a cohort of patients receiving pemetrexed-based chemotherapy with durvalumab outside...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2025-05-01
|
| Seri Bilgileri: | JTO Clinical and Research Reports |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2666364324001450 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|